About abeona therapeutics - ABEO
Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in Cleveland, OH.
ABEO At a Glance
Abeona Therapeutics, Inc.
6555 Carnegie Avenue
Cleveland, Ohio 44103
| Phone | 1-646-813-4701 | Revenue | 5.82M | |
| Industry | Pharmaceuticals: Major | Net Income | 71.18M | |
| Sector | Health Technology | Employees | 226 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
ABEO Valuation
| P/E Current | 5.423 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 5.196 |
| Price to Sales Ratio | 59.886 |
| Price to Book Ratio | 1.822 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -2.12 |
| Enterprise Value to Sales | 31.289 |
| Total Debt to Enterprise Value | 0.137 |
ABEO Efficiency
| Revenue/Employee | 25,752.212 |
| Income Per Employee | 314,969.027 |
| Receivables Turnover | 0.867 |
| Total Asset Turnover | 0.035 |
ABEO Liquidity
| Current Ratio | 6.93 |
| Quick Ratio | 6.744 |
| Cash Ratio | 6.473 |
ABEO Profitability
| Gross Margin | -2.646 |
| Operating Margin | -1,536.907 |
| Pretax Margin | 1,224.794 |
| Net Margin | 1,223.076 |
| Return on Assets | 43.127 |
| Return on Equity | 70.046 |
| Return on Total Capital | 38.648 |
| Return on Invested Capital | 61.516 |
ABEO Capital Structure
| Total Debt to Total Equity | 15.682 |
| Total Debt to Total Capital | 13.556 |
| Total Debt to Total Assets | 11.289 |
| Long-Term Debt to Equity | 7.463 |
| Long-Term Debt to Total Capital | 6.451 |